Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 200 Leukemia, Lymphocytic, Chronic, B-Cell 54 Recurrence 37 Neoplasms, Plasma Cell 30 Lymphoma, Mantle-Cell 30 Lymphoma 30 Lymphoma, Follicular 29 Lymphoma, Large B-Cell, Diffuse 27 Leukemia 23 Leukemia, Myeloid, Acute 22 Lymphoma, Non-Hodgkin 21 Lymphoma, B-Cell, Marginal Zone 15 Myelodysplastic Syndromes 13 Hodgkin Disease 12 Waldenstrom Macroglobulinemia 8 Prostatic Neoplasms 8 Lymphoma, T-Cell 8 Smoldering Multiple Myeloma 7 Immunoglobulin Light-chain Amyloidosis 7 Neoplasms 6 Melanoma 6 Lymphoma, B-Cell 6 Hematologic Diseases 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, T-Cell, Cutaneous 5 Lymphoma, Large-Cell, Anaplastic 5 Leukemia, Myelomonocytic, Chronic 5 Hematologic Neoplasms 5 Amyloidosis 5 Sezary Syndrome 4

Interventions

Paclitaxel 2 Tocotrienols 1 Lenalidomide 1 EP-100 membrane-disrupting peptide 1 Carboplatin 1 Bevacizumab 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Ovarian Cancer Recurrent × Lenalidomide × Clear all

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡